| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2022 | 36.05% | RBC Capital | $36 → $32 | Maintains | Outperform |
| 05/17/2022 | 14.8% | Credit Suisse | $28 → $27 | Maintains | Neutral |
| 05/10/2022 | 53.06% | RBC Capital | $42 → $36 | Maintains | Outperform |
| 03/16/2022 | 19.05% | Credit Suisse | $37 → $28 | Maintains | Neutral |
| 03/07/2022 | 78.57% | RBC Capital | $47 → $42 | Maintains | Outperform |
| 01/18/2022 | 48.81% | B of A Securities | $40 → $35 | Maintains | Buy |
| 01/18/2022 | 99.83% | RBC Capital | $50 → $47 | Maintains | Outperform |
| 08/10/2021 | 65.82% | Credit Suisse | $37 → $39 | Maintains | Neutral |
| 05/10/2021 | 95.58% | Deutsche Bank | $42 → $46 | Maintains | Buy |
| 03/01/2021 | 44.56% | Credit Suisse | $32 → $34 | Maintains | Neutral |
| 01/05/2021 | 14.8% | Credit Suisse | $22 → $27 | Maintains | Neutral |
| 11/02/2020 | -6.46% | Credit Suisse | $19 → $22 | Maintains | Neutral |
| 08/04/2020 | 10.54% | Deutsche Bank | $24 → $26 | Maintains | Buy |
| 08/03/2020 | -19.22% | Credit Suisse | $18 → $19 | Maintains | Neutral |
| 06/16/2020 | -36.22% | B of A Securities | $18 → $15 | Downgrades | Neutral → Underperform |
| 05/04/2020 | -23.47% | Credit Suisse | $23 → $18 | Maintains | Neutral |
| 04/24/2020 | 2.04% | Deutsche Bank | $33 → $24 | Maintains | Buy |
| 04/03/2020 | -2.21% | Credit Suisse | $29 → $23 | Maintains | Neutral |
| 03/24/2020 | 6.29% | Benchmark | $33 → $25 | Reiterates | → Buy |
| 02/24/2020 | 40.31% | Deutsche Bank | $22 → $33 | Maintains | Buy |
| 11/04/2019 | -2.21% | Benchmark | $21 → $23 | Maintains | Buy |
| 09/17/2019 | -6.46% | Deutsche Bank | → $22 | Initiates Coverage On | → Buy |
| 05/17/2019 | -23.47% | JMP Securities | → $18 | Upgrades | Market Perform → Market Outperform |
| 01/07/2019 | -31.97% | Credit Suisse | $21 → $16 | Maintains | Neutral |
| 12/14/2018 | -14.97% | Barclays | → $20 | Initiates Coverage On | → Equal-Weight |
| 11/05/2018 | -10.71% | Credit Suisse | $18 → $21 | Maintains | Neutral |
| 10/16/2018 | -23.47% | Credit Suisse | → $18 | Initiates Coverage On | → Neutral |
| 02/27/2018 | — | JMP Securities | Upgrades | Market Underperform → Market Perform | |
| 01/30/2018 | 10.54% | Wells Fargo | → $26 | Reinstates | → Outperform |
Select Medical Hldgs Questions & Answers
The latest price target for Select Medical Hldgs (NYSE: SEM) was reported by RBC Capital on November 7, 2022. The analyst firm set a price target for $32.00 expecting SEM to rise to within 12 months (a possible 36.05% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Select Medical Hldgs (NYSE: SEM) was provided by RBC Capital, and Select Medical Hldgs maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Select Medical Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Select Medical Hldgs was filed on November 7, 2022 so you should expect the next rating to be made available sometime around November 7, 2023.
While ratings are subjective and will change, the latest Select Medical Hldgs (SEM) rating was a maintained with a price target of $36.00 to $32.00. The current price Select Medical Hldgs (SEM) is trading at is $23.52, which is out of the analyst's predicted range.